Losartan Cost in Connecticut 2026

What Does Losartan Actually Cost in Connecticut in 2026?

Generic losartan potassium tablets cost approximately $10 per month at retail pharmacies across Connecticut in 2026 when paying cash or using a free discount card. Branded Cozaar carries a manufacturer list price near $80 per month, though insurers and pharmacy benefit managers negotiate that down sharply. Virtually no prescriber writes Cozaar today because the generic is therapeutically identical.

At chains including CVS, Walgreens, Walmart, and Stop and Shop locations throughout Hartford, New Haven, Bridgeport, and Stamford, a 30-day supply of generic losartan 50 mg runs between $4 and $15 depending on which discount card is applied. GoodRx, RxSaver, and Blink Health all operate in Connecticut and routinely return prices at or below $10 for a 30-tablet supply. A 90-day supply through Walmart's $10 generic program or Costco Pharmacy can cut the per-dose cost further, sometimes reaching $0.11 per tablet. The FDA approved losartan potassium (Cozaar) in April 1995 for hypertension and later in 2001 specifically for diabetic nephropathy in patients with type 2 diabetes and elevated serum creatinine [1].

Losartan belongs to the angiotensin II receptor blocker (ARB) class. It blocks the AT1 receptor, reducing vasoconstriction and aldosterone secretion [2]. The key LIFE trial (N=9,193, Lancet 2002) compared losartan 50 to 100 mg to atenolol 50 to 100 mg in hypertensive patients with left ventricular hypertrophy. Losartan reduced the primary composite endpoint of cardiovascular death, stroke, or myocardial infarction by 13% (relative risk 0.87 to 95% CI 0.77, 0.98, P=0.021) and reduced stroke specifically by 25% [3]. Those outcomes support its continued first-line use across many guidelines and make cost accessibility directly relevant to patient health.

The American Heart Association and American College of Cardiology 2017 Hypertension Guideline notes that ARBs are acceptable first-line agents for hypertension, particularly in patients with chronic kidney disease or diabetes, where they may slow nephropathy progression [4]. Given that Connecticut's adult hypertension prevalence is roughly 33% per CDC data, the number of state residents who could benefit from affordable ARB therapy is substantial [5].

Connecticut Medicaid (HUSKY Health) Coverage for Losartan

HUSKY Health covers losartan, but a prior authorization (PA) is required in most cases before the claim processes at the pharmacy. The PA requirement is standard for ARBs under Connecticut's Medicaid preferred drug list (PDL) and typically asks the prescriber to document that the patient has a covered indication (hypertension, heart failure with reduced ejection fraction, or diabetic nephropathy) and, in some pathways, that an ACE inhibitor was tried first or is contraindicated.

Once PA is approved, HUSKY Health members pay $0 to $3 per fill at participating pharmacies. The approval turnaround is usually 24 to 72 hours for a standard review. An urgent PA can be processed same-day if the prescriber documents clinical urgency. Connecticut's HUSKY A, HUSKY B, HUSKY C, and HUSKY D programs all use the same PDL, so the PA pathway is consistent across enrollment categories [6].

Prescribers submitting PA requests should include the diagnosis code (I10 for essential hypertension, E11.65 for type 2 diabetes with hyperglycemia, or N18.x for CKD stage), current blood pressure readings, and any contraindication to ACE inhibitors such as a history of ACE-inhibitor-induced angioedema. Angioedema risk with ACE inhibitors affects approximately 0.1 to 0.7% of users and is more common in Black patients [7]. Because losartan does not inhibit bradykinin breakdown, it does not carry the same angioedema risk as ACE inhibitors, making it a preferred alternative in those patients.

The JNC 8 guideline (JAMA 2014) states: "In the general black population, including those with diabetes, thiazide-type diuretics or CCBs are recommended; however, for CKD patients of any race with proteinuria, ACEIs or ARBs are preferred." [8] That recommendation directly supports PA approval in CKD patients on HUSKY Health.

How Private Insurance Covers Losartan in Connecticut

Most commercial plans in Connecticut, including Anthem, Aetna, ConnectiCare, Harvard Pilgrim, and UnitedHealthcare, place generic losartan on Tier 1 or Tier 2 of their formularies. Tier 1 copays typically run $0, $10 per 30-day fill. Tier 2 copays are usually $15, $40. Branded Cozaar, if still covered at all, sits on Tier 3 or higher, with copays of $40, $100 or more.

For patients on high-deductible health plans (HDHPs), the full cash price applies until the deductible is met. In that scenario, using a GoodRx card instead of insurance often returns a lower price than the insurance-adjudicated rate. Patients should ask their pharmacist to run both options before checkout, as pharmacies are required to inform patients of lower-cost alternatives under Connecticut's 2019 pharmacy transparency legislation [9].

Employer-sponsored plans regulated under ERISA follow federal formulary rules rather than Connecticut state insurance mandates, so coverage terms may differ from fully-insured state-regulated plans. If a drug is excluded from an ERISA plan formulary, the patient's best option is usually a discount card or manufacturer assistance.

Medicare Part D beneficiaries in Connecticut will find losartan on most plan formularies at $0, $5 per fill in the low-income subsidy (Extra Help) program, or at standard Tier 1, 2 copays otherwise [10]. Open enrollment runs October 15 through December 7 each year, and beneficiaries should use the Medicare Plan Finder tool at cms.gov to compare formulary placements annually.

Is Compounded Losartan Legal in Connecticut?

Compounded losartan is legal in Connecticut when prepared by a 503A pharmacy operating under a valid prescription for an identified individual patient. Connecticut's Department of Consumer Protection (DCP) licenses and inspects compounding pharmacies. A 503A facility may compound losartan if there is a documented patient-specific clinical need that an FDA-approved commercial product cannot meet, such as an alternative dosage strength, a liquid formulation for patients who cannot swallow tablets, or an allergen-free base.

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, may not compound losartan because it is not on the FDA's current 503B bulks list [11]. Any Connecticut pharmacy representing itself as a 503B compounder dispensing losartan without individual prescriptions would be operating outside federal guidance.

For telehealth patients, some platforms pair prescriptions with 503A pharmacies that offer compounded losartan at very low or no out-of-pocket cost to the patient, with the cost absorbed into the platform's subscription or service fee. That model is legal as long as the prescription is issued by a licensed Connecticut prescriber following a valid prescriber-patient relationship and the pharmacy holds a valid Connecticut DCP license [12].

Patients should ask compounding pharmacies for a certificate of analysis (COA) confirming potency, sterility (if applicable), and absence of contaminants. The FDA's guidance on pharmacy compounding notes that compounded products lack the pre-market efficacy and safety review of approved drugs, so sourcing from a licensed, inspected facility is the appropriate safeguard [11].

The Clinical Case for Losartan: Trials and Dosing That Inform Prescribing

Understanding why losartan is prescribed helps Connecticut patients and providers decide whether cost barriers justify switching therapies or pursuing assistance programs. The drug has three FDA-approved indications: hypertension, reduction of stroke risk in hypertensive patients with left ventricular hypertrophy, and nephropathy in type 2 diabetics [1].

The LIFE trial randomized 9,193 patients with hypertension and electrocardiographic LVH to losartan-based or atenolol-based therapy for a mean of 4.8 years. Losartan reduced fatal or nonfatal stroke by 25% (relative risk 0.75, P=0.001) compared to atenolol despite similar blood pressure reductions, suggesting a blood-pressure-independent benefit [3]. That stroke data is the basis for the specific LVH indication on the FDA label.

For diabetic nephropathy, the RENAAL trial (N=1,513) tested losartan 50 to 100 mg versus placebo in patients with type 2 diabetes and nephropathy. Losartan reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (P=0.022) and reduced the risk of ESRD alone by 28% (P=0.002) [13]. The IDNT trial (N=1,715) similarly showed irbesartan, another ARB, reduced nephropathy progression, reinforcing the ARB class benefit in this population [14].

Typical starting doses are 25 to 50 mg once daily for hypertension, titrated to 100 mg once daily as needed. For nephropathy, the RENAAL protocol used 50 mg with uptitration to 100 mg [13]. Dose adjustment is not required for renal impairment, but patients with hepatic impairment or volume depletion should start at 25 mg [1].

The most common adverse effect is dizziness, reported in approximately 3 to 4% of patients in trials. Hyperkalemia is a concern in CKD patients, particularly those also taking potassium-sparing diuretics or potassium supplements. Serum potassium and creatinine should be checked at baseline and roughly 2 to 4 weeks after starting therapy, per standard nephrology practice [15].

Telehealth Prescribing of Losartan in Connecticut

Telehealth prescribers licensed in Connecticut may prescribe losartan following a valid synchronous or asynchronous encounter that satisfies Connecticut's prescribing standard of care. Connecticut expanded telehealth parity under Public Act 21-9, requiring insurers to cover telehealth services at payment parity with in-person visits for many services [16]. That parity applies to evaluation and management visits during which hypertension is diagnosed or managed.

A prescriber conducting a telehealth visit for hypertension management must document blood pressure readings (self-reported or from a validated home device), review the patient's medication history, assess contraindications (pregnancy, bilateral renal artery stenosis, prior ARB/ACE angioedema), and establish a monitoring plan for renal function and electrolytes. Losartan is category D in pregnancy and is contraindicated. Women of childbearing potential should use effective contraception and be counseled about that risk at every visit [1].

Several national telehealth platforms serve Connecticut residents, including HealthRX, Teladoc, MDLive, and Cerebral Health. Prescription costs vary by platform. On platforms that partner with 503A pharmacies, the net patient cost for compounded losartan may be $0 per month. On standard platforms where the patient fills at a retail pharmacy, the $4, $15 range with a discount card applies.

The Connecticut Medical Examining Board's telehealth guidelines require that the prescriber review at least one set of validated blood pressure readings and that a follow-up plan be in place within 90 days for new hypertension prescriptions. Patients using home blood pressure monitors should use an upper-arm cuff validated against the European Society of Hypertension protocol list, as wrist cuffs show higher inaccuracy rates in clinical validation studies [17].

Losartan Discount Programs and Savings Cards in Connecticut

Multiple cost-reduction pathways exist for Connecticut residents who pay out of pocket or face high copays. The options range from free discount cards to manufacturer programs and state pharmaceutical assistance.

GoodRx and RxSaver. Both programs are free to use and require no insurance. Presenting a GoodRx card at most Connecticut retail pharmacies returns generic losartan prices between $4 and $15 per 30-day supply depending on dose and chain. Prices update daily and vary by zip code, so checking the current price at a specific pharmacy before driving there is worth the 30-second search.

Merck Patient Assistance Program (PAP). Merck offers patient assistance for branded Cozaar through its Merck Patient Assistance Program for patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level) and who lack insurance coverage for the drug. Given that generic losartan is available for $4, $15 per month, this program is mainly relevant for the rare patient whose insurer covers only Cozaar or who has a documented intolerance to certain generic excipients [18].

Connecticut Pharmaceutical Assistance Contract to the Elderly and Disabled (PACE/PACPLUS). Connecticut's PACE program assists residents aged 65 and older or adults with disabilities who meet income thresholds. PACE provides a co-pay benefit on prescription drugs, and losartan qualifies as a covered medication. The DCP administers enrollment, and applications are available through the Connecticut DSS [19].

Medicare Extra Help (Low-Income Subsidy). Federal LIS reduces Part D drug costs to near $0 for qualifying beneficiaries. In Connecticut, roughly 130,000 Medicare beneficiaries are estimated to qualify for Extra Help but have not yet enrolled, per CMS data [10]. Enrollment is through Social Security Administration (SSA) or the Medicare website.

340B Program. Federally qualified health centers (FQHCs), Ryan White HIV/AIDS program sites, and certain Connecticut hospitals participate in the 340B drug pricing program. Patients receiving care at a 340B-participating entity may access losartan at 340B pricing, which is substantially below retail. Connecticut FQHCs include Community Health Center Inc., Fair Haven Community Health Care, and Chase Brescia Community Health Center, among others [20].

Monitoring Requirements and Safety Considerations

Starting losartan correctly matters as much as the cost of getting it. Baseline labs should include a basic metabolic panel (BMP) for serum creatinine, BUN, potassium, and sodium. Repeat BMP at 2 to 4 weeks after initiation and after any dose increase. If serum creatinine rises more than 30% above baseline after starting losartan, assess for bilateral renal artery stenosis or volume depletion before continuing [15].

Blood pressure targets differ by indication. For most adults with hypertension, the 2017 ACC/AHA guideline recommends a target of <130/80 mmHg [4]. For CKD patients with proteinuria, the KDIGO 2021 guidelines recommend <120/80 mmHg systolic if tolerated [21]. For elderly patients (aged 65 and older), the 2017 guideline recommends <130/80 mmHg for those who are ambulatory and community-dwelling.

Drug interactions worth noting in Connecticut prescribing practice: NSAIDs (ibuprofen, naproxen) blunt ARB antihypertensive effects and may worsen renal function when combined with losartan, particularly in older patients [22]. Potassium supplements and potassium-sparing diuretics such as spironolactone raise hyperkalemia risk, and that combination requires closer electrolyte monitoring. Lithium levels increase when ARBs are co-prescribed due to reduced renal lithium clearance.

Salt substitutes that replace sodium chloride with potassium chloride pose a practical and underappreciated risk. Several case reports and a systematic review of 11 studies found that potassium-based salt substitutes significantly raise serum potassium in CKD patients on RAAS-blocking agents [23]. Prescribers and patients in Connecticut should discuss this during counseling, especially given the marketing of salt substitutes as "heart-healthy" alternatives.

How to Access Losartan Through HealthRX in Connecticut

HealthRX serves Connecticut residents through a fully licensed telehealth platform. A prescriber licensed in Connecticut conducts a synchronous video or asynchronous intake visit, reviews uploaded blood pressure logs, medication history, and relevant labs, and issues a prescription to the patient's chosen pharmacy or to a partner 503A compounding pharmacy.

The intake process typically takes 15 to 20 minutes. Most patients receive a prescription decision within 24 hours for asynchronous intakes. Follow-up visits at 4 to 8 weeks review blood pressure response, tolerance, and lab results. HealthRX's clinical protocols require a BMP before or within 30 days of starting losartan and repeat labs at 4 weeks, consistent with standard nephrology and cardiology practice [15].

For HUSKY Health patients, HealthRX can assist with prior authorization documentation. The prescribing clinician submits a PA form directly to Connecticut Medicaid on behalf of the patient, including diagnosis codes, blood pressure history, and any ACE inhibitor contraindications. Approval rates for losartan PA requests with complete documentation are high. A 2022 CMS report found that PA approval rates for preferred generic medications on state Medicaid PDLs exceeded 85% when complete clinical documentation was submitted at the time of the initial request [24].

Patients using private insurance should confirm their plan's tier placement before their first fill. The HealthRX care team can provide a letter of medical necessity if a plan requires one to move losartan to a lower cost tier, though for a Tier 1, 2 generic this is rarely needed.

The lowest net cost pathway for most uninsured or underinsured Connecticut residents in 2026: a GoodRx card at Walmart or Costco Pharmacy, targeting a 90-day supply of generic losartan 50 mg, which runs approximately $10, $14 for 90 tablets at those chains. That brings the monthly cost to roughly $3.50 to $4.70.